



**BROAD INTELLIGENCE INTERNATIONAL PHARMACEUTICAL HOLDINGS LIMITED**

**博智國際藥業控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1149)**

## **UNUSUAL PRICE AND TURNOVER MOVEMENT**

This announcement is made at the request of The Stock Exchange of Hong Kong Limited.

The board of directors (the “**Board**”) of Broad Intelligence International Pharmaceutical Holdings Limited (the “**Company**”) has noted the increase in the price of the shares and increase in trading volume of the shares of the Company today and wishes to state that the Board is not aware of any other reasons for such increase in price and increase in trading volume.

The Board also confirms that there are no negotiations or agreements relating to intended acquisitions or realizations which are discloseable under rule 13.23 of the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”), neither is the Board aware of any matter discloseable under the general obligation imposed by rule 13.09 of the Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board, the directors of which individually and jointly accept responsibility for the accuracy of this announcement.

By Order of the Board

**Broad Intelligence International Pharmaceutical Holdings Limited**

**Zhong Houtai**

*Chairman*

Hong Kong, 5 November 2008

Websites: [www.broadintelligence.com.hk](http://www.broadintelligence.com.hk)

[www.irasia.com/listco/hk/broadintelligence](http://www.irasia.com/listco/hk/broadintelligence)

*As at the date of this announcement, the executive directors of the Company are Mr. Zhong Houtai, Mr. Zhong Houyao, Mr. Chong Hoi Fung, Mr. Sun Daquan, and Mr. Cheung Chuen, Mr. Pei Renjiu and Mr. Li Kai Ming are the independent non-executive directors of the Company.*